Xu Junyue, Jia Xingwang, Zhang Xueguang, Jiao Xiaocui, Zhang Shana, Zhao Yahong, Wu Xiaohong, Li Yi, Liu Xuetong, Yu Qian
Department of Clinical Laboratory, Capital Medical University Electric Power Teaching Hospital, Beijing, China.
Department of Nephrology, Capital Medical University Electric Power Teaching Hospital, Beijing, China.
Br J Hosp Med (Lond). 2024 Dec 30;85(12):1-14. doi: 10.12968/hmed.2024.0474. Epub 2024 Dec 27.
The present study aimed to assess the capability of biomarkers, including inflammatory indicators, anaemic markers, lipid markers, and renal function indices, to differentiate between different stages of chronic kidney disease (CKD). Expected to provide a new strategy for monitoring the development of CKD and stratified treatment management, providing valuable insights for future biomarker studies to explore early detection of CKD. The changes in inflammatory markers (interferon gamma [IFN-γ], interleukin [IL]-17A, IL-10, IL-6, IL-4, IL-2, IL-1 and white blood cells [WBC]), lipid markers (high-density lipoprotein cholesterol [HDL-c], low-density lipoprotein cholesterol [LDL-c], and triglyceride [TG]), indicators of kidney injury (serum creatinine [Scr] and blood urea nitrogen [BUN]) in 451 patients with different stages of CKD were examined. Furthermore, these markers were compared between 299 anemic patients and 53 non-anemic patients. Univariate and multivariate regression analyses were employed to analyze the association between these biomarkers and estimated glomerular filtration rate (eGFR). To identify risk factors associated with the development of CKD, we utilized principal component analysis to evaluate their utility as potential diagnostic and prognostic markers for the disease. Significant differences were found in IL-6, BUN, and hemoglobin (Hb) levels across CKD stages 2 to 5. Anaemic individuals had elevated levels of IL-6, Scr, and BUN compared to non-anaemic individuals. In addition, the multivariate linear regression analysis revealed that IL-1 ( = 0.022), IL-6 ( = 0.022), Hb ( < 0.001), and BUN ( < 0.001) were statistically significant predictors of eGFR. Furthermore, it was discovered that the blood levels of IL-6 ( = 0.012), BUN ( < 0.001), and Hb ( < 0.001) were risk factors associated with the stages of CKD. Serum levels of IL-6, BUN and Hb have been associated with the progression of CKD. Using a combination of serum biomarkers is a potential strategy for tracking the development of CKD, facilitating stratified management and early intervention.
本研究旨在评估生物标志物（包括炎症指标、贫血标志物、血脂标志物和肾功能指标）区分慢性肾脏病（CKD）不同阶段的能力。期望为监测CKD的发展和分层治疗管理提供新策略，为未来探索CKD早期检测的生物标志物研究提供有价值的见解。检测了451例不同阶段CKD患者炎症标志物（γ干扰素[IFN-γ]、白细胞介素[IL]-17A、IL-10、IL-6、IL-4、IL-2、IL-1和白细胞[WBC]）、血脂标志物（高密度脂蛋白胆固醇[HDL-c]、低密度脂蛋白胆固醇[LDL-c]和甘油三酯[TG]）、肾损伤指标（血清肌酐[Scr]和血尿素氮[BUN]）的变化。此外，比较了299例贫血患者和53例非贫血患者的这些标志物。采用单因素和多因素回归分析来分析这些生物标志物与估计肾小球滤过率（eGFR）之间的关联。为了确定与CKD发展相关的危险因素，我们利用主成分分析来评估它们作为该疾病潜在诊断和预后标志物的效用。在CKD 2至5期，IL-6、BUN和血红蛋白（Hb）水平存在显著差异。与非贫血个体相比，贫血个体的IL-6、Scr和BUN水平升高。此外，多因素线性回归分析显示，IL-1（=0.022）、IL-6（=0.022）、Hb（<0.001）和BUN（<0.001）是eGFR的统计学显著预测因子。此外，发现IL-6（=0.012）、BUN（<0.001）和Hb（<0.001）的血水平是与CKD分期相关的危险因素。血清IL-6、BUN和Hb水平与CKD的进展有关。联合使用血清生物标志物是跟踪CKD发展、促进分层管理和早期干预的潜在策略。
